Vaginal micronised progesterone for the prevention of hypertensive disorders of pregnancy: A systematic review and meta-analysis
- PMID: 37941309
- DOI: 10.1111/1471-0528.17705
Vaginal micronised progesterone for the prevention of hypertensive disorders of pregnancy: A systematic review and meta-analysis
Abstract
Background: Treatment with vaginal progesterone reduces the risk of miscarriage and preterm birth in selected high-risk women. The hypothesis that vaginal progesterone can reduce the risk of hypertensive disorders of pregnancy (HDP) is unexplored.
Objectives: To summarise the evidence on the effectiveness of vaginal progesterone to reduce the risk of HDP.
Search strategy: We searched Embase (OVID), MEDLINE (OVID), PubMed, CENTRAL and clinicaltrials.gov from inception until 20 June 2023.
Selection criteria: We included placebo-controlled randomised trials (RCTs) of vaginal progesterone for the prevention or treatment of any pregnancy complications.
Data collection and analysis: We extracted absolute event numbers for HDP and pre-eclampsia in women receiving vaginal progesterone or placebo, and meta-analysed the data with a random effects model. We appraised the certainty of the evidence using GRADE methodology.
Main results: The quantitative synthesis included 11 RCTs, of which three initiated vaginal progesterone in the first trimester, and eight in the second or third trimesters. Vaginal progesterone started in the first trimester of pregnancy lowered the risk of any HDP (risk ratio [RR] 0.71, 95% confidence interval [CI] 0.53-0.93, 2 RCTs, n = 4431 women, I2 = 0%; moderate-certainty evidence) and pre-eclampsia (RR 0.61, 95% CI 0.41-0.92, 3 RCTs, n = 5267 women, I2 = 0%; moderate-certainty evidence) when compared with placebo. Vaginal progesterone started in the second or third trimesters was not associated with a reduction in HDP (RR 1.19, 95% CI 0.67-2.12, 3 RCTs, n = 1602 women, I2 = 9%; low-certainty evidence) or pre-eclampsia (RR 0.97, 95% CI 0.71-1.31, 5 RCTs, n = 4274 women, I2 = 0%; low-certainty evidence).
Conclusions: Our systematic review found first-trimester initiated vaginal micronised progesterone may reduce the risk of HDP and pre-eclampsia.
Keywords: hypertensive disorders of pregnancy; pre‐eclampsia; progesterone.
© 2023 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd.
Similar articles
-
Progestogens for preventing miscarriage: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD013792. doi: 10.1002/14651858.CD013792.pub2. Cochrane Database Syst Rev. 2021. PMID: 33872382 Free PMC article.
-
Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems.Cochrane Database Syst Rev. 2018 Oct 1;10(10):CD001059. doi: 10.1002/14651858.CD001059.pub5. Cochrane Database Syst Rev. 2018. PMID: 30277579 Free PMC article.
-
Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse.Cochrane Database Syst Rev. 2022 Aug 24;8(8):CD012396. doi: 10.1002/14651858.CD012396.pub2. Cochrane Database Syst Rev. 2022. PMID: 36000704 Free PMC article. Review.
-
Cervical pessary for preventing preterm birth in singleton pregnancies.Cochrane Database Syst Rev. 2022 Dec 1;12(12):CD014508. doi: 10.1002/14651858.CD014508. Cochrane Database Syst Rev. 2022. PMID: 36453699 Free PMC article. Review.
-
Calcium supplementation commencing before or early in pregnancy, for preventing hypertensive disorders of pregnancy.Cochrane Database Syst Rev. 2019 Sep 16;9(9):CD011192. doi: 10.1002/14651858.CD011192.pub3. Cochrane Database Syst Rev. 2019. PMID: 31523806 Free PMC article.
Cited by
-
Strategies for Safeguarding High-Risk Pregnancies From Preterm Birth: A Narrative Review.Cureus. 2024 Mar 7;16(3):e55737. doi: 10.7759/cureus.55737. eCollection 2024 Mar. Cureus. 2024. PMID: 38586732 Free PMC article. Review.
References
REFERENCES
-
- Wang W, Xie X, Yuan T, Wang Y, Zhao F, Zhou Z, et al. Epidemiological trends of maternal hypertensive disorders of pregnancy at the global, regional, and national levels: a population‐based study. BMC Pregnancy Childbirth. 2021;21(1):364.
-
- Connealy BD, Carreno CA, Kase BA, Hart LA, Blackwell SC, Sibai BM. A history of prior preeclampsia as a risk factor for preterm birth. Am J Perinatol. 2014;31(6):483–488.
-
- Rasmussen S, Ebbing C, Irgens LM. Predicting preeclampsia from a history of preterm birth. PLoS One. 2017;12(7):e0181016.
-
- Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco MC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613–622.
-
- van Vliet EOG, Askie LA, Mol BWJ, Oudijk MA. Antiplatelet agents and the prevention of spontaneous preterm birth: a systematic review and meta‐analysis. Obstet Gynecol. 2017;129(2):327–336.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical